Logo

Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)

Share this

Servier's Asparlas (calaspargase pegol-mknl) Receives FDA's Approval for Acute Lymphoblastic Leukemia (ALL)

Shots:

  • The approval is based on study assessing Asparlas (2500 U/m2- IV- q3w) in combination with multiagent chemotherapy in 124 patients with B-cell lineage ALL
  • The study resulted in achievement and maintenance of nadir serum asparaginase activity above the level of 0.1 U/mL
  • Asparlas (calaspargase pegol-mknl- IV) is an asparagine specific enzyme approved as a combination therapy for patients with ALL aged 1 month to 21 yr

Ref: The US FDA | Image: WSJ

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions